-
Technology
-
Services
-
Drug Development Partnerships
-
Expand your drug discovery capacity, shoulder to shoulder with our scientific team. Proprietary human disease biology in the OrganoPlate® platform. Together we make the therapeutics of tomorrow.
-
-
Custom Model & Assay Development
-
We create novel human tissue and disease models in the OrganoPlate® platform. Our experts are looking forward to developing assays according to your specifications.
-
-
Compound profiling & Screening
-
Get robust compound data in human tissue models through our services. With proven phenotypic assays in the OrganoPlate® platform, we support your drug discovery and development needs.
-
-
All Services
-
We offer several services to support your drug discovery and development needs. Find the overview here.
-
-
-
Products
-
OrganoPlate®
-
OrganoPlate® 2-lane 96
Supporting up to 96 tissue models on a single plate.
-
OrganoPlate® 3-lane 40
Supporting up to 40 tissue models on a single plate.
-
OrganoPlate® 3-lane 64
Supporting up to 64 tissue models on a single plate.
-
OrganoPlate® Graft
The first in vitro tissue culture platform that allows co-culture of spheroids, organoids, and tumors with a perfused microvascular bed and vascularization of 3D tissues.
-
-
OrganoStart Packages
-
Start today with 3D tissue modeling
Kickstart your first experiments with the OrganoPlate® through our OrganoStart packages.
-
-
OrganoReady®
-
OrganoReady® Organoid
Offering 40 or 64 ready-to-use ASC-derived organoid tubules for drug exposure, transport, and permeability studies.
-
OrganoReady® Collagen
Offering 40 or 64 ready-to-use chips pre-seeded with Collagen-I for faster, and more flexible workflow.
-
OrganoReady® Colon Caco-2
Offering 40 or 64 ready-to-use Caco-2 tubules to assess gut permeability, compound toxicity, and transport.
-
OrganoReady® Blood-Brain Barrier HBMEC
Offering 40 or 64 ready-to-use HBMEC tubules to quantify blood-brain barrier permeability, compound toxicity, and transport.
-
OrganoReady® Blood Vessel HUVEC
Offering 40 or 64 ready-to-use HUVEC tubules to quantify vascular toxicity, compound transport, and immune migration.
-
OrganoReady® Angiogenesis HUVEC
Offering 40 or 64 ready-to-sprout HUVEC tubules to quantify compound toxicity, and pro- or anti-angiogenic activity. -
OrganoReady® Vascular Bed HUVEC
Offering 64 ready-to-use HUVEC vascular beds for your vascularization studies.
-
-
Instruments
-
OrganoFlow®
Driving precisely-controlled perfusion flow in the OrganoPlate® platform
-
OrganoTEER®
Enabling fast, automated, and impedance-based TEER measurements in OrganoPlate®. Assay 40 or 64 tissue culture chips with a few clicks, in less than two minutes.
-
-
Workshops & Trainings
-
Start today with 3D tissue modeling
Kickstart your experiments with the most sophisticated 3D tissue culture platform. Find out which training fits your 3D tissue modeling needs best.
-
-
All Products
-
OrganoPlate® is the solution for all in vitro tissue culture applications. Explore the entire OrganoPlate® family and its dedicated instruments here.
-
-
Request a quote
-
Thinking of using OrganoPlate for your research? Request a quote for the product(s) of your interest.
-
-
-
Applications
-
Perfused Tubules
-
Layered tissues with perfused tubules in the absence of artificial membranes form the heart of our permeability and transport science. Study cell interactions, permeability, absorption, transport, and transcytosis without physical barriers.
-
-
Cell-Cell Interactions
-
Co-culture layered & structured tissues without artificial membranes with perfect imaging, to study barrier-free cellular interactions, cell-cell signaling, and migration.
-
-
3D Cell Migration
-
Evaluate the effect of chemotactic triggers or cells on the migration of cells through an extracellular matrix.
-
-
Angiogenesis
-
Membrane-free microvascular formation and growth through an extracellular matrix (ECM).
-
-
Vascularization
-
The missing link in tissue culture: add perfusable human vasculature to your tissue models, and recreate sophisticated microenvironments with OrganoPlate® Graft.
-
-
All Applications
-
OrganoPlate® enables you to study relevant 3D tissue biology by incorporating perfused tubules, co-culture, and full control over the tissue microenvironment. Find the overview of applications here.
-
-
-
Resources & Support
-
Knowledge Center
-
Visit our Knowledge Center to get up to speed with 3D tissue culture and to learn how OrganoPlate® supports your research needs.
Read our publications, application notes, watch our webinars, or check out the supporting protocols and brochures. All compiled for you, by our scientists.
-
-
Publications
-
Get inspired by peer-reviewed publications of our scientists, partners, and customers around the globe.
-
-
Case Studies
-
Get inspired by research done by our scientists, partners, and customers around the globe.
-
-
Blogs
-
Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
-
-
Workshops & Trainings
-
Kickstart your experiments with the most sophisticated 3D tissue culture platform. Find out which training fits your 3D tissue modeling needs best.
-
-
Technical Support
-
Any support questions about purchasing, products, or 3D tissue culture and analysis? Get in touch with our experts.
-
-
Request a quote
-
Thinking of using OrganoPlate for your research? Request a quote for the product(s) of your interest.
-
-
FAQ
-
Frequently asked questions answered by our experts. Find here the answer you're looking for.
-
-
-
Knowledge Center
-
About Mimetas
History
In the picture from left to right, are Paul Vulto (CEO), Jos Joore (CEO), Bas Trietsch (CTO), and Jacquelien ten Dam (CFO). Together they are forming the management team of MIMETAS. Paul, Jos, and Bas founded MIMETAS in 2013 in Leiden, the Netherlands. Since then, Paul and Jos have been CEOs, whereas Bas is now serving as CTO. In that same year, MIMETAS incorporated her US-branch in Gaithersburg (MD). Also, the Dutch-Belgian biotech company Galapagos (Euronext & NASDAQ: GLPG) became MIMETAS’ launching customer. MIMETAS expanded rapidly over the years. The company is now working with nearly all major pharmaceutical companies and many top-tier academic institutes. In 2018, MIMETAS opened a subsidiary in Tokyo to expand its presence in Asia. In 2019, the management team has been expanded and strengthened with the addition of Jacquelien ten Dam, serving as CFO.
Today, MIMETAS counts over 100 employees in four sites in the Netherlands, USA, and Japan.
In 2014, MIMETAS raised a Series A investment round of 5.6 million USD, followed by a Series B round of 21 million USD in 2018
Mission
MIMETAS strives to contribute to groundbreaking therapies with unique human disease biology, revealed by robust, screenable assays in the most versatile technology platform.
Vision
We believe that phenotypic tissue- and disease modeling is at the heart of 21st-century therapy development.
Board of Directors
Chairman - Dhaval Patel
Executive board members
Jos Joore - CEO, Mimetas
Paul Vulto - CEO, Mimetas
Non-executive board members
André Hoekema - Galapagos
François Valencony - OMX Europe Venture Fund
Edward Willems - Gold Nest Private Capital
Eric van der Putten - Aglaia Oncology Funds
Scientific Advisor - Patrice Denèfle
Core Values
Highly talented, friendly, and energetic people from all over the world have found their way to MIMETAS. It is these people that embody our core values by their sheer character and qualities. We call this ‘MIMETAS-do’. It's the way we roll.
At one of our company retreats, we asked our colleagues to put MIMETAS-do into words. And as you know: a picture is worth a thousand words. Check the image for the result.
Wondering what it's like to work with or at MIMETAS? Try us and find out.
